Activation of lymphocytes and increased interleukin-5 levels in bronchoalveolar lavage fluid in acute eosinophilic pneumonia

European Respiratory Journal

Volumn 13, Issue 1, 1999, Pages 217-220

  Taniguchi, H ^b   Kadota, J I ^a   Fujii, T ^a   Matsubara, Y I ^a   Katoh, S ^b   Mukae, H ^b   Matsukura, S ^b   Kohno, S ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

Acute eosinophilic pneumonia; Bronchoalveolar lavage fluid; Interleukin 5; Lymphocyte activation

Indexed keywords

CD11B ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 5; METHYLPREDNISOLONE;

ADULT; ARTICLE; CASE REPORT; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LOEFFLER PNEUMONIA; LUNG LAVAGE; LYMPHOCYTE ACTIVATION; PRIORITY JOURNAL; STEROID THERAPY; T LYMPHOCYTE SUBPOPULATION; THORAX RADIOGRAPHY;

ACUTE DISEASE; ADULT; BRONCHOALVEOLAR LAVAGE FLUID; FEMALE; HUMANS; INTERLEUKIN-5; LYMPHOCYTE ACTIVATION; PULMONARY EOSINOPHILIA;

EID: 0033028902     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3003.1999.13a40.x     Document Type: Article

References (16)

1. Allen JN, Pacht ER, Gadek JE, Davis WB. Acute eosinophilic pneumonia as a reversible cause of noninfectious respiratory failure. N Engl J Med 1989; 321: 569-574.
2. Buchheit J, Eid N, Rodgers G, Feger T, Yakoub O. Acute eosinophilic pneumonia with respiratory failure: a new syndrome? Am Rev Respir Dis 1992; 145: 716-718.
3. Imokawa S, Sato A, Hayakawa H, Toyoshima M, Taniguchi M, Chida K. Possible involvement of an environmental agent in the development of acute eosinophilic pneumonia. Ann Allergy Asthma Immunol 1996; 76: 419-422.
4. Miyazaki E, Sugisaki K, Shigenaga T, et al. A case of acute eosinophilic pneumonia caused by inhalation of Trichosporon terrestre. Am J Respir Crit Care Med 1995; 151: 541-543.
5. Okubo Y, Hossain M, Kai R, et al. Adhesion molecules on eosinophils in acute eosinophilic pneumonia. Am J Respir Crit Care Med 1995; 151: 1259-1262.
6. Yamaguchi S, Okubo Y, Hossain M, et al. IL-5 predominant in bronchoalveolar lavage fluid and peripheral blood in a patient with acute eosinophilic pneumonia. Intern Med 1995; 34: 65-68.
7. Lopez AF, Sanderson CJ, Gamble JR, Campbell HD, Young IG, Vadas MA. Recombinant human interleukin 5 is a selective activator of human eosinophil chemoattractant. J Exp Med 1988; 167: 219-224.
8. Wang JM, Rambaldi A, Biondi A, Chen ZG, Sanderson CJ, Mantovani A. Recombinant human interleukin 5 is a selective eosinophil chemoattractant. Eur J Immunol 1989; 19: 701-705.
9. Allen JN, Liao Z, Wewers MD, Altenberger EA, Moore SA, Allen ED. Detection of IL-5 and IL-1 receptor antagonists in bronchoalveolar lavage fluid in acute eosinophilic pneumonia. J Allergy Clin Immunol 1996; 97: 1366-1374.
10. Cantrell DA, Smith KA. Transient expression of interleukin 2 receptors. J Exp Med 1983; 158: 1895-1911.
11. Walker C, Bauer W, Braun RK et al. Activated T cells and cytokines in bronchoalveolar lavages from patients with various lung disease associated with eosinophilia. Am J Respir Crit Care Med 1994; 150: 1038-1048.
12. Okudaira H, Nagami M, Matsuzaki G, et al. T-cell-dependent accumulation of eosinophils in the lung and its inhibition by monoclonal anti-interleukin-5. Int Arch Allergy Appl Immunol 1991; 94: 171-173.
13. Schleimer RP, Bochner BS. The effects of glucocorticoids on human eosinophils. J Allergy Clin Immunol 1994; 94: 1202-1213.
14. Corrigan CJ, Hamid Q, North J, et al. Peripheral blood CD4 but not CD8 T-lymphocytes in patients with exacerbation of asthma transcribe and translate messenger RNA encoding cytokines which prolong eosinophil survival in the context of a Th2-type pattern: effect of glucocorticoid therapy. Am J Respir Cell Mol Biol 1995; 12: 567-578.
15. Myou S, Fujimura M, Yasui M, Ueno T, Matsuda T. Bronchoalveolar lavage cell analysis in measles viral pneumonia. Eur Respir J 1993; 6: 1437-1442.
16. Clement L, Dagg M, Landy A. Characterization of human lymphocyte subpopulations: alloreactive cytoxic T-lymphocyte precursor and effector cells are phenotypically distinct from Leu2+ suppressor cells. J Clin Immunol 1984; 4: 395-402.